Inactive Instrument

Medivation Inc Share Price

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

28/16/28	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
08/16/08	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE

28/16/28	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
08/16/08	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE
08/16/08	Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	RE
04/16/04	Medivation : Ex-Oppenheimer adviser arrested for trading on Pfizer employee's tips	RE
02/16/02	Medivation : sets eligibility date for shareholder consent on board revamp	RE
26/16/26	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
26/16/26	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
25/16/25	Exclusive: Sanofi to unveil challenge to Medivation's board - sources	RE
10/16/10	Astellas Pharma : Medivation succumbs to pressure to explore sale - sources	RE
09/16/09	Exclusive - Medivation succumbs to pressure to explore sale: sources	RE
06/16/06	Medivation : Sanofi ready to up offer for drugmaker Medivation, could oust board	RE
04/16/04	Medivation : Sanofi sees 'strong strategic' fit with U.S. Medivation	RE
04/16/04	Exclusive: Pfizer approaches Medivation about potential takeover - sources	RE

09/16/09	Medivation : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo	BU
09/16/09	Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit Against Medivation, Inc.	PR
07/16/07	MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.	PR
26/16/26	Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
26/16/26	Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders	BU

28/16/28	Sanofi : relève ses prévisions pour 2016 et s'envole en Bourse
28/16/28	Sanofi : relève ses prévisions pour 2016 et veut céder ses activités génériques en Europe
10/16/10	Medivation : Neue, im Rahmen der ESMO 2016 präsentierte Ergebnisse belegen zusätzlich, dass XTANDITM▼ (Enzalutamid) die Zeit bis zur PSA-Progression bei fortgeschrittenem Prostatakarzinom im Vergleich zu Placebo signifikant verlängert
10/16/10	Medivation : De nouvelles données présentées au Congrès 2016 de l’ESMO démontrent une fois de plus que XTANDITM▼ (enzalutamide) améliore nettement, par rapport au placebo, le délai avant progression du PSA en cas de cancer de la prostate avancé
19/16/19	Sanofi : poursuit Merck en justice aux USA pour protéger les brevets de Lantus

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	5.87TCr
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	5.39TCr
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	2.47TCr
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	2.42TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	1.88TCr
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	1.76TCr
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	1.63TCr
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	1.4TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	1.39TCr
Average	+2.87%	+7.20%	+54.64%	+148.04%	2.69TCr
Weighted average by Cap.	+2.44%	+5.62%	+59.06%	+138.48%

Employees

Sector